A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure
Status:
Completed
Trial end date:
1999-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects on heart rate and ventricular arrhythmias
(irregular heart beats) of two doses of Natrecor® (a recombinant form of the natural human
peptide normally secreted by the heart in response to heart failure) versus dobutamine,
during the first 24 hours of treatment of decompensated congestive heart failure (CHF).